| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_f1d684ccb6b9db56948b993776a58cc9
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_259de1b1b6c5512868ec29379824a1c1 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-496
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P27-02
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P27-06 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-496
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P27-06
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P27-02 |
| filingDate |
2018-08-13-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_5630b91215e5fd898561ca5fda0fe620
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_d7b340c3b16df31cc26d58f9fee0a837
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_70cd06cf7cdf09b51a17e3dda4ee608c
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_34bac0fa509640b27cf708262a3eb9b9
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_c03f2b36a5a727686f6e09f8a9cd7342
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_3ca1daaff4fe11eb2ae3e6c33ac6cb49
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_4cfe811efa89d2b1f19d9823a2630621
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_77b31763360675f0e19532537ab652da
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_6dd1af7243738f10ab6e66ffebb58081 |
| publicationDate |
2019-02-13-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
EP-3441069-A1 |
| titleOfInvention |
Treatment of ophthalmic conditions such as macular degeneration, glaucoma, and diabetic retinopathy using pharmaceutical agents that eliminate senescent cells |
| abstract |
This invention is based on the discovery that many eye conditions associated with aging are mediated at least in part by cells bearing a senescent phenotype. Senescent cells accumulate with age, and express factors that contribute to the pathophysiology of age related conditions. The data show that in age-matched patients, the severity of age-related conditions correlates with the abundance of senescent cells, and that clearing senescent cells can help abrogate the condition. Small molecule drugs that remove senescent cells from affected tissue in the eye are provided as part of this invention that have special efficacy in treating ophthalmic conditions. They not only inhibit progression of the disease, they can also reverse some of the pathophysiology -such as neovascularization and vaso-obliteration -that lead to vision loss. These senolytic agents have an appropriate dose and specificity profile to be effective in the clinical management of previously intractable ophthalmic conditions. |
| isCitedBy |
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-11129838-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-10981892-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-2019213160-A1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-2019213153-A1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-11666608-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-10717722-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-2022202877-A1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-10588916-B2 |
| priorityDate |
2017-08-11-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |